Elizabeth Pomfret
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 128 | 2025 | 754 | 18.160 |
Why?
| | Living Donors | 76 | 2025 | 272 | 13.550 |
Why?
| | Tissue and Organ Procurement | 39 | 2025 | 309 | 7.980 |
Why?
| | Tissue Donors | 18 | 2025 | 395 | 3.440 |
Why?
| | Hepatectomy | 25 | 2025 | 240 | 3.270 |
Why?
| | Donor Selection | 16 | 2024 | 74 | 3.150 |
Why?
| | Kidney Transplantation | 16 | 2025 | 658 | 2.620 |
Why?
| | End Stage Liver Disease | 12 | 2023 | 72 | 2.400 |
Why?
| | Organ Transplantation | 16 | 2025 | 242 | 2.280 |
Why?
| | Perfusion | 8 | 2025 | 225 | 2.020 |
Why?
| | Liver | 42 | 2023 | 1807 | 2.000 |
Why?
| | Patient Selection | 14 | 2023 | 680 | 1.940 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2023 | 339 | 1.870 |
Why?
| | Liver Neoplasms | 10 | 2023 | 719 | 1.570 |
Why?
| | Postoperative Complications | 27 | 2024 | 2716 | 1.490 |
Why?
| | Resource Allocation | 5 | 2025 | 50 | 1.460 |
Why?
| | Waiting Lists | 16 | 2025 | 242 | 1.370 |
Why?
| | Liver Cirrhosis | 9 | 2020 | 277 | 1.340 |
Why?
| | Tissue and Organ Harvesting | 10 | 2024 | 74 | 1.310 |
Why?
| | Graft Survival | 19 | 2025 | 490 | 1.280 |
Why?
| | Humans | 182 | 2025 | 138972 | 1.090 |
Why?
| | Laparoscopy | 3 | 2023 | 452 | 0.970 |
Why?
| | Fatty Liver | 6 | 2023 | 230 | 0.940 |
Why?
| | United States | 43 | 2025 | 15074 | 0.940 |
Why?
| | Organ Preservation | 6 | 2025 | 107 | 0.930 |
Why?
| | Informed Consent | 3 | 2024 | 188 | 0.930 |
Why?
| | Hepatitis C, Chronic | 5 | 2022 | 146 | 0.930 |
Why?
| | Lung Transplantation | 3 | 2025 | 313 | 0.910 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 52 | 0.890 |
Why?
| | Liver Diseases | 5 | 2023 | 290 | 0.850 |
Why?
| | Immunotoxins | 4 | 2025 | 55 | 0.780 |
Why?
| | Consensus Development Conferences as Topic | 2 | 2020 | 33 | 0.760 |
Why?
| | Graft Rejection | 13 | 2020 | 534 | 0.750 |
Why?
| | Consensus | 9 | 2024 | 683 | 0.750 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 143 | 0.720 |
Why?
| | Surgeons | 3 | 2025 | 327 | 0.690 |
Why?
| | Liver Failure | 7 | 2016 | 80 | 0.690 |
Why?
| | Adult | 75 | 2025 | 38393 | 0.680 |
Why?
| | Frailty | 1 | 2023 | 172 | 0.630 |
Why?
| | Middle Aged | 69 | 2025 | 33782 | 0.630 |
Why?
| | Portal Vein | 4 | 2017 | 108 | 0.610 |
Why?
| | Diphtheria Toxin | 4 | 2025 | 65 | 0.600 |
Why?
| | Pain, Postoperative | 3 | 2016 | 309 | 0.600 |
Why?
| | Male | 87 | 2025 | 68250 | 0.590 |
Why?
| | Female | 86 | 2025 | 74016 | 0.590 |
Why?
| | Treatment Outcome | 34 | 2025 | 10921 | 0.550 |
Why?
| | Immunosuppressive Agents | 6 | 2018 | 848 | 0.540 |
Why?
| | Transplant Recipients | 7 | 2025 | 174 | 0.530 |
Why?
| | Survival Rate | 14 | 2025 | 1934 | 0.520 |
Why?
| | Hepatic Veins | 5 | 2016 | 31 | 0.520 |
Why?
| | Kidney Failure, Chronic | 4 | 2025 | 575 | 0.510 |
Why?
| | Healthcare Disparities | 6 | 2025 | 662 | 0.500 |
Why?
| | Thrombelastography | 6 | 2023 | 157 | 0.500 |
Why?
| | Antiviral Agents | 4 | 2022 | 733 | 0.480 |
Why?
| | Blood Coagulation Disorders | 4 | 2022 | 176 | 0.470 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 264 | 0.470 |
Why?
| | Transplantation, Homologous | 8 | 2020 | 406 | 0.470 |
Why?
| | Venous Thrombosis | 1 | 2017 | 190 | 0.460 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2017 | 26 | 0.460 |
Why?
| | Biopsy | 9 | 2020 | 1072 | 0.460 |
Why?
| | Societies, Medical | 4 | 2024 | 835 | 0.440 |
Why?
| | Retrospective Studies | 31 | 2025 | 15901 | 0.430 |
Why?
| | Sirolimus | 1 | 2016 | 277 | 0.420 |
Why?
| | Interleukin-2 | 4 | 2024 | 451 | 0.410 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 229 | 0.410 |
Why?
| | Biliary Tract Diseases | 2 | 2010 | 34 | 0.410 |
Why?
| | Kidney | 6 | 2023 | 1467 | 0.410 |
Why?
| | Hepacivirus | 7 | 2022 | 238 | 0.390 |
Why?
| | Periodicals as Topic | 1 | 2015 | 211 | 0.380 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 1058 | 0.380 |
Why?
| | Registries | 6 | 2025 | 2081 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2697 | 0.370 |
Why?
| | Risk Factors | 17 | 2025 | 10385 | 0.360 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 115 | 0.360 |
Why?
| | Hepatitis C | 5 | 2022 | 247 | 0.360 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 43 | 0.360 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5152 | 0.340 |
Why?
| | Liver Regeneration | 4 | 2003 | 45 | 0.340 |
Why?
| | Allografts | 3 | 2023 | 141 | 0.330 |
Why?
| | Prognosis | 10 | 2025 | 3995 | 0.330 |
Why?
| | Resuscitation | 2 | 2024 | 275 | 0.320 |
Why?
| | Biliary Tract | 1 | 2008 | 14 | 0.300 |
Why?
| | Directed Tissue Donation | 1 | 2008 | 5 | 0.300 |
Why?
| | Blood Coagulation | 5 | 2023 | 262 | 0.300 |
Why?
| | Bioethical Issues | 1 | 2008 | 8 | 0.300 |
Why?
| | Patient Safety | 1 | 2012 | 332 | 0.300 |
Why?
| | Time Factors | 16 | 2025 | 6869 | 0.290 |
Why?
| | Vascular Surgical Procedures | 1 | 2011 | 325 | 0.290 |
Why?
| | Terminology as Topic | 3 | 2024 | 243 | 0.280 |
Why?
| | Interpersonal Relations | 1 | 2011 | 413 | 0.280 |
Why?
| | Adolescent | 23 | 2024 | 21581 | 0.280 |
Why?
| | Severity of Illness Index | 8 | 2023 | 2849 | 0.280 |
Why?
| | Quality of Life | 7 | 2020 | 2962 | 0.280 |
Why?
| | Software | 2 | 2012 | 670 | 0.270 |
Why?
| | Transplants | 2 | 2022 | 38 | 0.270 |
Why?
| | Aged | 31 | 2025 | 24172 | 0.270 |
Why?
| | Tacrolimus | 3 | 2020 | 191 | 0.260 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2006 | 16 | 0.260 |
Why?
| | Fibrinolysis | 3 | 2023 | 147 | 0.260 |
Why?
| | Young Adult | 12 | 2024 | 13371 | 0.250 |
Why?
| | Transplantation Immunology | 1 | 2006 | 31 | 0.240 |
Why?
| | Insurance, Life | 1 | 2005 | 2 | 0.240 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2152 | 0.240 |
Why?
| | International Cooperation | 2 | 2016 | 202 | 0.230 |
Why?
| | CD47 Antigen | 1 | 2025 | 37 | 0.230 |
Why?
| | Flank Pain | 1 | 2024 | 10 | 0.220 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 26 | 0.220 |
Why?
| | Renal Nutcracker Syndrome | 1 | 2024 | 9 | 0.220 |
Why?
| | Intestines | 2 | 2007 | 356 | 0.220 |
Why?
| | Health Care Rationing | 3 | 2013 | 59 | 0.220 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1569 | 0.220 |
Why?
| | Skin Neoplasms | 2 | 2023 | 837 | 0.210 |
Why?
| | Decision Making | 1 | 2011 | 947 | 0.210 |
Why?
| | Solitary Kidney | 1 | 2023 | 2 | 0.210 |
Why?
| | Critical Care | 4 | 2024 | 653 | 0.210 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 581 | 0.210 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 276 | 0.200 |
Why?
| | Sezary Syndrome | 1 | 2023 | 45 | 0.200 |
Why?
| | Risk Assessment | 9 | 2022 | 3466 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 60 | 0.200 |
Why?
| | Body Mass Index | 2 | 2024 | 2390 | 0.200 |
Why?
| | Congresses as Topic | 1 | 2024 | 228 | 0.200 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 1377 | 0.190 |
Why?
| | Length of Stay | 3 | 2023 | 1237 | 0.190 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 33 | 0.190 |
Why?
| | Body Temperature | 1 | 2023 | 223 | 0.190 |
Why?
| | Operative Time | 1 | 2023 | 149 | 0.190 |
Why?
| | Death | 3 | 2023 | 125 | 0.190 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2023 | 74 | 0.180 |
Why?
| | Thrombosis | 3 | 2022 | 374 | 0.180 |
Why?
| | Bile Ducts | 2 | 2022 | 67 | 0.180 |
Why?
| | Sodium | 1 | 2022 | 196 | 0.180 |
Why?
| | Massachusetts | 2 | 2012 | 175 | 0.180 |
Why?
| | Case-Control Studies | 5 | 2023 | 3574 | 0.180 |
Why?
| | Antibiotic Prophylaxis | 2 | 2020 | 121 | 0.170 |
Why?
| | Evidence-Based Medicine | 3 | 2016 | 743 | 0.170 |
Why?
| | Cause of Death | 3 | 2025 | 433 | 0.170 |
Why?
| | Sex Factors | 3 | 2024 | 2050 | 0.170 |
Why?
| | Cholangitis, Sclerosing | 3 | 2009 | 56 | 0.170 |
Why?
| | Recurrence | 10 | 2011 | 1085 | 0.170 |
Why?
| | Prothrombin Time | 1 | 2000 | 35 | 0.170 |
Why?
| | Predictive Value of Tests | 5 | 2020 | 2030 | 0.170 |
Why?
| | Physicians | 2 | 2010 | 930 | 0.170 |
Why?
| | Prospective Studies | 11 | 2020 | 7661 | 0.170 |
Why?
| | Diagnostic Imaging | 2 | 2013 | 320 | 0.170 |
Why?
| | Bupivacaine | 1 | 2000 | 38 | 0.170 |
Why?
| | Reperfusion | 1 | 2020 | 44 | 0.170 |
Why?
| | Temperature | 1 | 2023 | 660 | 0.170 |
Why?
| | Educational Status | 3 | 2022 | 475 | 0.170 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 176 | 0.170 |
Why?
| | Analgesia, Epidural | 1 | 2000 | 40 | 0.160 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2020 | 9 | 0.160 |
Why?
| | Cholestasis | 1 | 2023 | 208 | 0.160 |
Why?
| | Thymidine Phosphorylase | 1 | 2020 | 14 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 980 | 0.160 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 49 | 0.160 |
Why?
| | Costs and Cost Analysis | 3 | 2024 | 223 | 0.160 |
Why?
| | Anesthetics, Local | 1 | 2000 | 98 | 0.160 |
Why?
| | Incidence | 6 | 2025 | 2830 | 0.160 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 90 | 0.160 |
Why?
| | Policy | 1 | 2021 | 149 | 0.160 |
Why?
| | Choline | 4 | 1989 | 131 | 0.160 |
Why?
| | Disease Progression | 5 | 2025 | 2752 | 0.150 |
Why?
| | Nephrectomy | 1 | 2020 | 155 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 267 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2012 | 3313 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 313 | 0.150 |
Why?
| | Medicare | 1 | 2024 | 792 | 0.150 |
Why?
| | Viremia | 1 | 2020 | 149 | 0.150 |
Why?
| | Biliary Atresia | 1 | 2020 | 153 | 0.150 |
Why?
| | Catheterization | 2 | 2023 | 182 | 0.150 |
Why?
| | Risk | 3 | 2016 | 913 | 0.150 |
Why?
| | Amyloid Neuropathies | 1 | 1998 | 1 | 0.140 |
Why?
| | Gastric Bypass | 1 | 2020 | 118 | 0.140 |
Why?
| | Age Distribution | 2 | 2011 | 401 | 0.140 |
Why?
| | Mice, SCID | 3 | 2025 | 368 | 0.140 |
Why?
| | Cohort Studies | 9 | 2025 | 5744 | 0.140 |
Why?
| | Bile Duct Diseases | 1 | 2017 | 12 | 0.140 |
Why?
| | Telomerase | 1 | 2020 | 247 | 0.140 |
Why?
| | Phlebography | 1 | 2017 | 37 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 549 | 0.140 |
Why?
| | Premature Birth | 1 | 2021 | 343 | 0.130 |
Why?
| | Prevalence | 3 | 2023 | 2745 | 0.130 |
Why?
| | Obesity, Morbid | 2 | 2020 | 271 | 0.130 |
Why?
| | Reoperation | 6 | 2017 | 579 | 0.130 |
Why?
| | Incidental Findings | 1 | 2017 | 79 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 90 | 0.130 |
Why?
| | Drug Overdose | 1 | 2021 | 346 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 122 | 0.130 |
Why?
| | North America | 3 | 2025 | 304 | 0.130 |
Why?
| | Bariatric Surgery | 1 | 2020 | 217 | 0.130 |
Why?
| | Child | 8 | 2022 | 21936 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 5884 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 1437 | 0.120 |
Why?
| | Social Determinants of Health | 1 | 2020 | 260 | 0.120 |
Why?
| | Communicable Diseases | 1 | 2017 | 161 | 0.120 |
Why?
| | Postoperative Period | 4 | 2020 | 355 | 0.120 |
Why?
| | Iron | 1 | 2017 | 324 | 0.120 |
Why?
| | Morbidity | 2 | 2013 | 321 | 0.120 |
Why?
| | Perioperative Care | 1 | 2017 | 213 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 273 | 0.110 |
Why?
| | Monitoring, Physiologic | 2 | 1994 | 280 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 870 | 0.110 |
Why?
| | Cadaver | 3 | 2015 | 295 | 0.110 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 117 | 0.110 |
Why?
| | Transplantation | 2 | 2024 | 33 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1522 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 859 | 0.110 |
Why?
| | Antilymphocyte Serum | 1 | 2014 | 59 | 0.110 |
Why?
| | Organ Size | 2 | 2012 | 471 | 0.110 |
Why?
| | Parents | 2 | 2020 | 1423 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 695 | 0.110 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 85 | 0.110 |
Why?
| | Withholding Treatment | 1 | 2014 | 77 | 0.110 |
Why?
| | Comorbidity | 1 | 2019 | 1657 | 0.100 |
Why?
| | Choline Deficiency | 3 | 1991 | 10 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 546 | 0.100 |
Why?
| | Steroids | 1 | 2014 | 163 | 0.100 |
Why?
| | Mitochondria | 1 | 2020 | 958 | 0.100 |
Why?
| | Splenorenal Shunt, Surgical | 2 | 2006 | 3 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 327 | 0.100 |
Why?
| | Physician Executives | 1 | 2013 | 31 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 660 | 0.100 |
Why?
| | Thoracic Injuries | 1 | 1993 | 66 | 0.100 |
Why?
| | Anticoagulants | 1 | 2017 | 667 | 0.100 |
Why?
| | Receptors, CCR4 | 2 | 2024 | 23 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2015 | 457 | 0.090 |
Why?
| | Catheterization, Central Venous | 1 | 1994 | 113 | 0.090 |
Why?
| | Personnel Selection | 1 | 2013 | 79 | 0.090 |
Why?
| | Therapeutic Equipoise | 1 | 2011 | 2 | 0.090 |
Why?
| | Liver Function Tests | 2 | 2020 | 105 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2015 | 302 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 593 | 0.090 |
Why?
| | Mice | 6 | 2025 | 17828 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 742 | 0.090 |
Why?
| | Religion | 1 | 2011 | 69 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3397 | 0.090 |
Why?
| | Anastomosis, Surgical | 1 | 2011 | 158 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2011 | 897 | 0.090 |
Why?
| | Family Relations | 1 | 2011 | 92 | 0.090 |
Why?
| | Health Status Indicators | 1 | 2011 | 166 | 0.080 |
Why?
| | Hepatitis, Autoimmune | 4 | 2006 | 15 | 0.080 |
Why?
| | Observer Variation | 1 | 2011 | 350 | 0.080 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 26 | 0.080 |
Why?
| | Animals | 14 | 2025 | 37243 | 0.080 |
Why?
| | Anesthesiology | 1 | 2013 | 159 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.080 |
Why?
| | Wounds, Nonpenetrating | 1 | 1993 | 303 | 0.080 |
Why?
| | Hypertension, Portal | 1 | 2010 | 64 | 0.080 |
Why?
| | Specialties, Surgical | 1 | 2011 | 76 | 0.080 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 238 | 0.080 |
Why?
| | Obesity | 4 | 2024 | 2994 | 0.080 |
Why?
| | Critical Illness | 1 | 2015 | 836 | 0.080 |
Why?
| | S-Adenosylmethionine | 1 | 1989 | 56 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 855 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 3984 | 0.070 |
Why?
| | Models, Biological | 2 | 2006 | 1810 | 0.070 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2009 | 59 | 0.070 |
Why?
| | Rats, Inbred Strains | 7 | 1991 | 345 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1281 | 0.070 |
Why?
| | Life Expectancy | 1 | 2009 | 70 | 0.070 |
Why?
| | Brain Death | 2 | 2024 | 46 | 0.070 |
Why?
| | Methionine | 1 | 1989 | 159 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 496 | 0.070 |
Why?
| | Ventilator Weaning | 1 | 2008 | 37 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2010 | 272 | 0.070 |
Why?
| | Lithium | 1 | 1988 | 42 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 1994 | 1109 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5591 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 663 | 0.070 |
Why?
| | Documentation | 2 | 2024 | 199 | 0.070 |
Why?
| | General Surgery | 1 | 2010 | 175 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2011 | 898 | 0.070 |
Why?
| | Hypotension | 1 | 2008 | 120 | 0.070 |
Why?
| | Heart Failure | 1 | 2020 | 2065 | 0.060 |
Why?
| | Prealbumin | 1 | 2006 | 30 | 0.060 |
Why?
| | Abdomen | 2 | 2024 | 135 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 2 | 2003 | 26 | 0.060 |
Why?
| | Survival Analysis | 4 | 2015 | 1311 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 814 | 0.060 |
Why?
| | Demography | 1 | 2007 | 298 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 35 | 0.060 |
Why?
| | Safety | 1 | 2008 | 348 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1370 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 130 | 0.060 |
Why?
| | Pain | 2 | 2022 | 779 | 0.060 |
Why?
| | Renal Veins | 1 | 2024 | 18 | 0.060 |
Why?
| | Canada | 1 | 2025 | 408 | 0.050 |
Why?
| | Algorithms | 2 | 2011 | 1730 | 0.050 |
Why?
| | Xanthomatosis | 1 | 2004 | 8 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1321 | 0.050 |
Why?
| | Swine, Miniature | 1 | 2024 | 90 | 0.050 |
Why?
| | Employment | 1 | 2005 | 181 | 0.050 |
Why?
| | Salvage Therapy | 1 | 2024 | 152 | 0.050 |
Why?
| | Granuloma | 1 | 2004 | 97 | 0.050 |
Why?
| | Bilirubin | 1 | 2023 | 89 | 0.050 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2003 | 14 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 116 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.050 |
Why?
| | Shock | 1 | 2024 | 101 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2014 | 1985 | 0.050 |
Why?
| | Laboratories | 1 | 2023 | 107 | 0.050 |
Why?
| | Depression | 2 | 2018 | 1470 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 85 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 64 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 377 | 0.050 |
Why?
| | Research | 1 | 2006 | 451 | 0.050 |
Why?
| | Infant | 3 | 2021 | 9577 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 86 | 0.050 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2002 | 19 | 0.050 |
Why?
| | Information Dissemination | 1 | 2024 | 223 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 209 | 0.050 |
Why?
| | Pain Measurement | 1 | 2024 | 549 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 1994 | 0.050 |
Why?
| | Propensity Score | 1 | 2023 | 314 | 0.050 |
Why?
| | Platelet Transfusion | 1 | 2022 | 72 | 0.050 |
Why?
| | Patients | 1 | 2023 | 180 | 0.040 |
Why?
| | RNA, Viral | 3 | 2013 | 684 | 0.040 |
Why?
| | Hypophosphatemia | 1 | 2001 | 17 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 485 | 0.040 |
Why?
| | Swine | 1 | 2024 | 800 | 0.040 |
Why?
| | Family | 1 | 2005 | 680 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 571 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 69 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 123 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 51 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 92 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 322 | 0.040 |
Why?
| | Thymidine | 1 | 2020 | 60 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 89 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 156 | 0.040 |
Why?
| | Preoperative Care | 1 | 2022 | 366 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 80 | 0.040 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 28 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6158 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 292 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 228 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2001 | 748 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 610 | 0.040 |
Why?
| | Hemangioma, Cavernous | 1 | 1999 | 14 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 380 | 0.040 |
Why?
| | HLA Antigens | 1 | 2020 | 233 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2023 | 445 | 0.040 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 130 | 0.040 |
Why?
| | Gastrectomy | 1 | 2020 | 132 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 427 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1924 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3276 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 668 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 428 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 317 | 0.040 |
Why?
| | Anatomic Variation | 1 | 2017 | 3 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2005 | 2850 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1765 | 0.030 |
Why?
| | Pancreas Transplantation | 2 | 2009 | 66 | 0.030 |
Why?
| | Hepcidins | 1 | 2017 | 22 | 0.030 |
Why?
| | Nervous System | 1 | 1998 | 67 | 0.030 |
Why?
| | Mammary Glands, Animal | 2 | 1988 | 130 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 67 | 0.030 |
Why?
| | Boston | 1 | 2017 | 94 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 522 | 0.030 |
Why?
| | Hepatic Artery | 3 | 2003 | 51 | 0.030 |
Why?
| | Phosphatidylcholines | 2 | 1988 | 136 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1355 | 0.030 |
Why?
| | Cardiovascular System | 1 | 1998 | 136 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 611 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 201 | 0.030 |
Why?
| | Communication | 1 | 2022 | 932 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1092 | 0.030 |
Why?
| | Acute-On-Chronic Liver Failure | 1 | 2015 | 5 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2020 | 1192 | 0.030 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 24 | 0.030 |
Why?
| | Hepatorenal Syndrome | 1 | 2015 | 13 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1409 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 337 | 0.030 |
Why?
| | Cross Infection | 1 | 1998 | 249 | 0.030 |
Why?
| | Contraindications | 2 | 2006 | 86 | 0.030 |
Why?
| | Benchmarking | 1 | 2016 | 187 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 86 | 0.030 |
Why?
| | Contrast Media | 2 | 2013 | 463 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 907 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 517 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 137 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 963 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 370 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2011 | 7685 | 0.030 |
Why?
| | Mesothelioma | 2 | 1985 | 45 | 0.030 |
Why?
| | Genotype | 2 | 2013 | 1849 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 278 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 661 | 0.030 |
Why?
| | Peritoneal Neoplasms | 2 | 1985 | 97 | 0.030 |
Why?
| | Equipment Failure | 1 | 1994 | 110 | 0.030 |
Why?
| | Constitution and Bylaws | 1 | 2013 | 1 | 0.030 |
Why?
| | Decision Trees | 1 | 1993 | 82 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2016 | 377 | 0.030 |
Why?
| | Hospitals, Low-Volume | 1 | 2013 | 23 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 70 | 0.020 |
Why?
| | Rabbits | 1 | 2014 | 762 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1645 | 0.020 |
Why?
| | Hospitals, High-Volume | 1 | 2013 | 44 | 0.020 |
Why?
| | Pediatrics | 1 | 2001 | 1079 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1991 | 590 | 0.020 |
Why?
| | Viral Envelope Proteins | 1 | 2013 | 97 | 0.020 |
Why?
| | Certification | 1 | 2013 | 117 | 0.020 |
Why?
| | Clinical Protocols | 1 | 1993 | 273 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1497 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 609 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 567 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 818 | 0.020 |
Why?
| | Patient Readmission | 1 | 2016 | 703 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 568 | 0.020 |
Why?
| | Education | 1 | 2011 | 110 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1070 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 1993 | 817 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1047 | 0.020 |
Why?
| | Biological Transport | 2 | 1988 | 403 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2047 | 0.020 |
Why?
| | Pregnancy | 2 | 2021 | 6870 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 1120 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 1993 | 324 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1993 | 326 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2004 | 1482 | 0.020 |
Why?
| | Folic Acid | 1 | 1991 | 186 | 0.020 |
Why?
| | Methotrexate | 1 | 1991 | 255 | 0.020 |
Why?
| | Ursodeoxycholic Acid | 1 | 2009 | 17 | 0.020 |
Why?
| | Cholagogues and Choleretics | 1 | 2009 | 5 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2010 | 85 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1989 | 135 | 0.020 |
Why?
| | Workload | 1 | 2011 | 162 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 1998 | 1068 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 394 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1031 | 0.020 |
Why?
| | Phosphatidylethanolamines | 1 | 1988 | 76 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 560 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 493 | 0.020 |
Why?
| | Life Style | 1 | 2011 | 484 | 0.020 |
Why?
| | Methyltransferases | 1 | 1988 | 72 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 226 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1949 | 0.020 |
Why?
| | Health Policy | 1 | 2011 | 398 | 0.020 |
Why?
| | Gastroenterology | 1 | 2010 | 176 | 0.020 |
Why?
| | Breast | 1 | 1988 | 158 | 0.020 |
Why?
| | Blood Glucose | 1 | 1998 | 2241 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 812 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 581 | 0.020 |
Why?
| | Betaine | 1 | 1988 | 64 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3636 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2011 | 513 | 0.020 |
Why?
| | Selenium Compounds | 1 | 1987 | 21 | 0.020 |
Why?
| | Selenium | 1 | 1987 | 47 | 0.020 |
Why?
| | Needs Assessment | 1 | 2010 | 381 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11158 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 1987 | 112 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4095 | 0.020 |
Why?
| | Fellowships and Scholarships | 1 | 2010 | 310 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2008 | 279 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 475 | 0.010 |
Why?
| | Survivors | 1 | 2009 | 501 | 0.010 |
Why?
| | Clinical Competence | 1 | 2013 | 1149 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 9 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5530 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 162 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1984 | 171 | 0.010 |
Why?
| | Tissue Adhesions | 1 | 2004 | 32 | 0.010 |
Why?
| | Lacerations | 1 | 2004 | 39 | 0.010 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2004 | 91 | 0.010 |
Why?
| | Curriculum | 1 | 2010 | 1008 | 0.010 |
Why?
| | Internship and Residency | 1 | 2013 | 1183 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1988 | 620 | 0.010 |
Why?
| | Angiography | 1 | 2003 | 207 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 2004 | 148 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 2002 | 11 | 0.010 |
Why?
| | Erythrocytes | 1 | 1988 | 701 | 0.010 |
Why?
| | Inflammation | 1 | 1993 | 2853 | 0.010 |
Why?
| | Azathioprine | 1 | 2001 | 49 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1737 | 0.010 |
Why?
| | Spleen | 1 | 2003 | 524 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 239 | 0.010 |
Why?
| | Ischemia | 1 | 2003 | 414 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2003 | 347 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 455 | 0.010 |
Why?
| | APACHE | 1 | 1998 | 64 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2001 | 563 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 224 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 266 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1939 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 1742 | 0.010 |
Why?
| | Combined Modality Therapy | 2 | 1985 | 1235 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1984 | 2533 | 0.010 |
Why?
| | Pteroylpolyglutamic Acids | 1 | 1991 | 1 | 0.010 |
Why?
| | Tetrahydrofolates | 1 | 1991 | 16 | 0.010 |
Why?
| | Phosphatidylethanolamine N-Methyltransferase | 1 | 1988 | 8 | 0.000 |
Why?
| | Hemicholinium 3 | 1 | 1988 | 2 | 0.000 |
Why?
| | Dinitrophenols | 1 | 1988 | 8 | 0.000 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 9 | 0.000 |
Why?
| | Ouabain | 1 | 1988 | 18 | 0.000 |
Why?
| | Osmolar Concentration | 1 | 1988 | 167 | 0.000 |
Why?
| | Methylation | 1 | 1988 | 227 | 0.000 |
Why?
| | Selenium Radioisotopes | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenious Acid | 1 | 1987 | 3 | 0.000 |
Why?
| | Selenomethionine | 1 | 1987 | 4 | 0.000 |
Why?
| | Milk | 1 | 1988 | 123 | 0.000 |
Why?
| | Lactation | 1 | 1988 | 179 | 0.000 |
Why?
| | Epithelium | 1 | 1988 | 316 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1988 | 1090 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1984 | 84 | 0.000 |
Why?
| | Kinetics | 1 | 1988 | 1649 | 0.000 |
Why?
| | Asbestos | 1 | 1983 | 37 | 0.000 |
Why?
| | Laparotomy | 1 | 1983 | 112 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1988 | 1103 | 0.000 |
Why?
| | Palliative Care | 1 | 1985 | 815 | 0.000 |
Why?
|
|
Pomfret's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|